Opinion|Videos|November 27, 2024

Real-World Outcomes in HER2-Positive NSCLC

Dr Heymach real-world outcomes versus clinical trials for HER2-positive NSCLC and the management of common adverse events associated with HER2-directed therapies.

Video content above is prompted by the following:

  • How do real-world patient outcomes for patients with HER 2 positive NSCLC compare to those seen in clinical trials?
  • What are the most common treatment-related adverse events observed with HER2-directed therapies, and how are they managed?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo